Let's take a detailed look at the dangers of using Ozempic: Reports link Ozempic to blindness and NAIOD, making it a risky ...

their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA approval for the would-be blockbuster. The US approval is the first in ...

The market for Diabetic Peripheral Neuropathy (DPN) pain relief includes several approved treatments, such as antiseizure drugs, antidepressants, opioids, and non-opioid pain medications.

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Neffy for severe allergic reactions and Dupixent for chronic obstructive pulmonary disease (COPD), which all gained FDA approval this year. These medications are "slated to make a big clinical ...

According to GlobalData, Phase I drugs for Neuropathy have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIR-2501’s ...

Diabetic peripheral neuropathy companies working in the market are Helixmith, Aptinyx, WinSanTor, Regenacy Pharmacuticals, Novaremed, Grünenthal, and others. LAS ...

Ibudilast is under clinical development by MediciNova and currently in Phase II for Chemotherapy Induced Peripheral Neuropathy ... data and analytics to create drugs-specific PTSR and LoA in the ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved ... made today’s approval possible.” Both drugs, administered ...

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royalties and up to $129 ...

The FDA approved tislelizumab plus chemotherapy for the first-line treatment of unresectable or metastatic gastric or GEJ adenocarcinoma. The FDA has approved tislelizumab-jsgr (Tevimbra) for use with ...

FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with steroid-refractory acute GVHD. The FDA approved remestemcel-L-rknd (Ryoncil) ...